{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:06:22Z","timestamp":1758845182477,"version":"3.44.0"},"reference-count":69,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000268","name":"Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Tuberc."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>The global challenge of tuberculosis (TB) is exacerbated by multidrug-resistant TB (MDR\/RR-TB), confounded by country-level differences in TB prevention and care. The impact of local differences in drug-resistance selection pressure and transmission may be observed by analyzing distributions of minimum inhibitory concentrations (MICs). Using the Bedaquiline Drug-Resistance Emergence Assessment in MDR-TB (DREAM) dataset, we analyzed MIC distributions derived from a standard protocol across 11 countries and 12 antibiotics to explore country-level variation in drug susceptibility.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We analyzed 71,135 MICs from 5,928 MDR\/RR-TB isolates sampled from bedaquiline-naive patients. We compared MIC distributions across countries and WHO resistance classes, then used Spearman rank correlations to compare the drug-susceptibility within individual isolates by country. To explore the effect of bedaquiline use on resistance, we used linear regression to compare bedaquiline MICs with WHO data on bedaquiline usage.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>MIC distributions between countries were heterogeneous, especially for fluoroquinolones and isoniazid. The correlation analysis revealed a relationship between bedaquiline and clofazimine MICs in six countries. Analysis of isolates by resistance class demonstrated that XDR-TB isolates had higher MICs than MDR-TB isolates for antibiotics not part of the XDR definition. We found limited evidence to suggest that past bedaquiline usage at the national level led to raised bedaquiline MICs in patients not exposed to the drug.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our research shows clear variations in drug susceptibility within <jats:italic>M. tuberculosis<\/jats:italic> across different countries and resistance classes, providing evidence of distinct drug-susceptibility dynamics per country. This expands the evidence for MDR-TB country differences and supports further country-specific policy development.<\/jats:p><\/jats:sec>","DOI":"10.3389\/ftubr.2025.1667354","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T05:28:22Z","timestamp":1758778102000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Country-level heterogeneity in MDR-TB drug susceptibility supports country-specific policy development"],"prefix":"10.3389","volume":"3","author":[{"given":"Naomi M.","family":"Fuller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas G.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy D.","family":"McHugh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gwenan M.","family":"Knight","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"B1","volume-title":"Global Tuberculosis Report 2024, 1st Edn","year":"2024"},{"key":"B2","volume-title":"WHO Consolidated Guidelines on Tuberculosis. Module 4: Treatment - Drug-Susceptible Tuberculosis Treatment, 1st edn","year":"2022"},{"key":"B3","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S1473-3099(07)70291-8","article-title":"Measuring tuberculosis burden, trends, and the impact of control programmes","volume":"8","author":"Dye","year":"2008","journal-title":"Lancet Infect Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e806","DOI":"10.1016\/S2214-109X(16)30199-1","article-title":"Feasibility of achieving the (2025). WHO global tuberculosis targets in South Africa, China, and India: a combined analysis of 11 mathematical models","volume":"4","author":"Houben","year":"2016","journal-title":"Lancet Glob Health."},{"key":"B5","unstructured":"MSF\n            \n            \n              Stop TB\n              Partnership\n            \n          \n          Step Up for TB 2020\n          \n          2020"},{"key":"B6","unstructured":"Country, Regional and Global TB Profiles"},{"key":"B7","first-page":"59","article-title":"Tuberculosis in Pakistan: a decade of progress, a future of challenge","author":"Vermund","year":"2009","journal-title":"J Pak Med Assoc"},{"key":"B8","unstructured":"WHO Releases New Global Lists of High-Burden Countries for TB, HIV-Associated TB and Drug-Resistant TB"},{"key":"B9","unstructured":"Meeting Report of the WHO Expert Consultation on the Definition of Extensively Drug-Resistant Tuberculosis\n          \n          2020"},{"key":"B10","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa2119430","article-title":"Bedaquiline\u2013pretomanid\u2013linezolid regimens for drug-resistant tuberculosis","volume":"387","author":"Conradie","year":"2022","journal-title":"N Engl J Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1183\/13993003.00724-2015","article-title":"Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis","volume":"47","author":"Pym","year":"2016","journal-title":"Eur Respir J."},{"key":"B12","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S2213-2600(23)00389-2","article-title":"Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial","volume":"12","author":"Nyang'wa","year":"2024","journal-title":"Lancet Respir Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e0002283","DOI":"10.1371\/journal.pgph.0002283","article-title":"Baseline and acquired resistance to bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanid","volume":"3","author":"Timm","year":"2023","journal-title":"PLoS Glob Public Health."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e012039","DOI":"10.1136\/bmjgh-2023-012039","article-title":"Estimating the prevalence of poor-quality anti-TB medicines: a neglected risk for global TB control and resistance","volume":"8","author":"Tabernero","year":"2023","journal-title":"BMJ Glob Health."},{"key":"B15","doi-asserted-by":"publisher","first-page":"76","DOI":"10.4236\/ojmm.2015.52009","article-title":"Low doses of rifampicin used in new tuberculosis patients correlated to increased frequency of rifampicin-resistance and poorer treatment outcomes","volume":"5","author":"Chen","year":"2015","journal-title":"Open J Med Microbiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1093\/jac\/dkm109","article-title":"Counterfeit or substandard antimicrobial drugs: a review of the scientific evidence","volume":"60","author":"Kelesidis","year":"2007","journal-title":"J Antimicrob Chemother."},{"key":"B17","doi-asserted-by":"publisher","first-page":"32","DOI":"10.5588\/pha.18.0078","article-title":"Barriers and facilitators to early access of bedaquiline and delamanid for MDR-TB: a mixed-methods study","volume":"9","author":"Rodriguez","year":"2019","journal-title":"Public Health Action."},{"key":"B18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/jac\/48.suppl_1.5","article-title":"Determination of minimum inhibitory concentrations","volume":"48","author":"Andrews","year":"2001","journal-title":"J Antimicrob Chemother."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e00141","DOI":"10.1128\/CMR.00141-20","article-title":"Mechanisms of drug-induced tolerance in Mycobacterium tuberculosis","volume":"34","author":"Goossens","year":"2020"},{"key":"B20","doi-asserted-by":"publisher","first-page":"244","DOI":"10.12688\/wellcomeopenres.21269.1","article-title":"distribution analysis identifies differences in AMR between population sub-groups","volume":"9","author":"Wildfire","year":"2024","journal-title":"Wellcome Open Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e00100","DOI":"10.1128\/cmr.00100-22","article-title":"Wild-type distributions of minimum inhibitory concentrations and epidemiological cut-off values\u2014laboratory and clinical utility","volume":"36","author":"Kahlmeter","year":"2023","journal-title":"Clin Microbiol Rev."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2200166","DOI":"10.1183\/13993003.00166-2022","article-title":"Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment","volume":"59","author":"Group","year":"2022","journal-title":"Eur Respir J"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e02919","DOI":"10.1128\/JCM.02919-20","article-title":"Bedaquiline drug resistance emergence assessment in multidrug-resistant tuberculosis (MDR-TB): a 5-year prospective in vitro surveillance study of bedaquiline and other second-line drug susceptibility testing in MDR-TB isolates","volume":"60","author":"Kaniga","year":"2022","journal-title":"J Clin Microbiol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e00062","DOI":"10.1128\/MMBR.00062-18","article-title":"Deciphering Within-Host Microevolution of Mycobacterium tuberculosis through Whole-Genome Sequencing: the Phenotypic Impact and Way Forward","volume":"83","author":"Ley","year":"2019","journal-title":"Microbiol Mol Biol Rev MMBR."},{"key":"B25","unstructured":"Johnson & Johnson - Bedaquiline Drug Resistance Assessment in MDR-TB (DREAM)"},{"key":"B26","unstructured":"Vivli AMR"},{"key":"B27","unstructured":"Breakpoint Tables for Interpretation of MICs and Zone Diameters, Version 5.0, Valid from 2015-01-01"},{"key":"B28","unstructured":"World Bank Country and Lending Groups \u2013 World Bank Data Help Desk"},{"key":"B29","unstructured":"Countries Overview"},{"key":"B30","unstructured":"Fuller\n              NM\n            \n          \n          nmfuller\/DREAM_MIC_distribution_NMF.: R Code Needed for Analysis of DREAM Database"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1213\/ANE.0000000000002864","article-title":"Correlation coefficients: appropriate use and interpretation","volume":"126","author":"Schober","year":"2018","journal-title":"Anesth Analg."},{"key":"B32","unstructured":"WHO TB Burden Estimates"},{"key":"B33","unstructured":"TB Data Dictionary"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e0119628","DOI":"10.1371\/journal.pone.0119628","article-title":"Genetic mutations associated with isoniazid resistance in Mycobacterium tuberculosis: a systematic review","volume":"10","author":"Seifert","year":"2015","journal-title":"PLoS ONE."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1128\/AAC.00112-06","article-title":"Bobadilla del Valle M, Cavatore M, Guerrero MI, Varma-Basil M, et al","volume":"50","author":"Hazb\u00f3n","year":"2006"},{"key":"B36","unstructured":"MSF\n            \n            \n              Stop TB\n              Partnership\n            \n          \n          Step up for TB Policies Tracker"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e102135","DOI":"10.1371\/journal.pone.0102135","article-title":"Acquired Resistance of Mycobacterium tuberculosis to bedaquiline","volume":"9","author":"Andries","year":"2014","journal-title":"PLoS ONE."},{"key":"B38","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1093\/jac\/dkw502","article-title":"Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline","volume":"72","author":"Villellas","year":"2017","journal-title":"J Antimicrob Chemother."},{"key":"B39","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-024-01289-5","article-title":"Detection of a historic reservoir of bedaquiline\/clofazimine resistance-associated variants in Mycobacterium tuberculosis","volume":"16","author":"Nimmo","year":"2024"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e00090","DOI":"10.1128\/spectrum.00090-23","article-title":"Spontaneous mutational patterns and novel mutations for bedaquiline and clofazimine resistance in Mycobacterium tuberculosis","volume":"11","author":"Shi","year":"2023"},{"key":"B41","doi-asserted-by":"publisher","first-page":"10444","DOI":"10.1038\/s41598-023-36955-y","article-title":"Bedaquiline- and clofazimine- selected Mycobacterium tuberculosis mutants: further insights on resistance driven largely by Rv0678","volume":"13","author":"Snobre","year":"2023","journal-title":"Sci Rep."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00915-19","article-title":"Acquisition of cross-resistance to bedaquiline and clofazimine following treatment for tuberculosis in Pakistan","author":"Ghodousi","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"B43","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1183\/09031936.00142914","article-title":"mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment","volume":"45","author":"Somoskovi","year":"2015","journal-title":"Eur Respir J."},{"key":"B44","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.ijid.2020.10.081","article-title":"Acquisition of clofazimine resistance following bedaquiline treatment for multidrug-resistant tuberculosis","volume":"102","author":"Liu","year":"2021","journal-title":"Int J Infect Dis."},{"key":"B45","doi-asserted-by":"publisher","first-page":"119301","DOI":"10.1016\/j.lfs.2021.119301","article-title":"Comprehensive review on mechanism of action, resistance and evolution of antimycobacterial drugs","volume":"274","author":"Chauhan","year":"2021","journal-title":"Life Sci."},{"key":"B46","year":"2020","journal-title":"Global Tuberculosis Report"},{"key":"B47","doi-asserted-by":"publisher","first-page":"7119","DOI":"10.1038\/ncomms8119","article-title":"Four decades of transmission of a multidrug-resistant Mycobacterium tuberculosis outbreak strain","volume":"6","author":"Eldholm","year":"2015","journal-title":"Nat Commun."},{"key":"B48","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1093\/cid\/cir904","article-title":"Additional drug resistance in Mycobacterium tuberculosis isolates from resected cavities among patients with multidrug-resistant or extensively drug-resistant pulmonary tuberculosis","volume":"54","author":"Kempker","year":"2012","journal-title":"Clin Infect Dis."},{"key":"B49","doi-asserted-by":"publisher","first-page":"7312","DOI":"10.1038\/s41467-021-27616-7","article-title":"Genomic signatures of pre-resistance in Mycobacterium tuberculosis","volume":"12","author":"Torres Ortiz","year":"2021"},{"key":"B50","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1038\/s41598-018-21378-x","article-title":"Isoniazid resistance levels of Mycobacterium tuberculosis can largely be predicted by high-confidence resistance-conferring mutations","volume":"8","author":"Lempens","year":"2018","journal-title":"Sci Rep."},{"key":"B51","unstructured":"WHO Consolidated Operational Handbook on Tuberculosis: Module 4: Treatment and Care\n          \n          2025"},{"key":"B52","unstructured":"36630546\n          WHO Consolidated Guidelines on Tuberculosis. Module 4: Treatment - Drug-Resistant Tuberculosis Treatment, 2022 Update\n          \n          2022"},{"key":"B53","unstructured":"Rapid Communication: Key Changes to Treatment of Multidrug- and Rifampicin-Resistant Tuberculosis (MDR\/RR-TB)\n          \n          2018"},{"key":"B54","doi-asserted-by":"publisher","first-page":"e165","DOI":"10.1016\/S2666-5247(20)30031-8","article-title":"van, Brien K, Moodley S, Wolf A, et al. Population-level emergence of bedaquiline and clofazimine resistance-associated variants among patients with drug-resistant tuberculosis in southern Africa: a phenotypic and phylogenetic analysis","volume":"1","author":"Nimmo","year":"2020","journal-title":"Lancet Microbe"},{"key":"B55","doi-asserted-by":"publisher","first-page":"2400391","DOI":"10.1183\/13993003.00391-2024","article-title":"A composite reference standard is needed for bedaquiline antimicrobial susceptibility testing for Mycobacterium tuberculosis complex","volume":"64","author":"K\u00f6ser","year":"2024","journal-title":"Eur Respir J."},{"key":"B56","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/jac\/dky414","article-title":"Oliveira R, Pinhata JMW, Chimara E, Pacheco Ascencio E, Puy\u00e9n Guerra ZM, et al. Bedaquiline and linezolid MIC distributions and epidemiological cut-off values for Mycobacterium tuberculosis in the Latin American region","volume":"74","author":"Lopez","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"B57","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.1128\/JCM.01123-16","article-title":"A multilaboratory, multicountry study to determine bedaquiline mic quality control ranges for phenotypic drug susceptibility testing","volume":"54","author":"Kaniga","year":"2016","journal-title":"J Clin Microbiol."},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00900-17","article-title":"In vitro drug susceptibility of bedaquiline, delamanid, linezolid, clofazimine, moxifloxacin, and gatifloxacin against extensively drug-resistant tuberculosis in Beijing, China","author":"Pang","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"B59","doi-asserted-by":"publisher","first-page":"e00165","DOI":"10.1128\/AAC.00165-18","article-title":"Comparison of in vitro activity and mic distributions between the novel oxazolidinone delpazolid and linezolid against multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis in China","volume":"62","author":"Zong","year":"2018","journal-title":"Antimicrob Agents Chemother."},{"key":"B60","doi-asserted-by":"publisher","first-page":"e0274426","DOI":"10.1371\/journal.pone.0274426","article-title":"Minimum inhibitory concentrations of rifampin and isoniazid among multidrug and isoniazid resistant Mycobacterium tuberculosis in Ethiopia","volume":"17","author":"Getahun","year":"2022","journal-title":"PLoS ONE"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.3389\/fmicb.2016.01947","article-title":"Correlation of rpoB mutations with minimal inhibitory concentration of rifampin and rifabutin in Mycobacterium tuberculosis in an HIV\/AIDS Endemic Setting, South Africa","volume":"7","author":"Rukasha","year":"2016","journal-title":"Front Microbiol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"2101925","DOI":"10.1183\/13993003.01925-2021","article-title":"Drug exposure and susceptibility of second-line drugs correlate with treatment response in patients with multidrug-resistant tuberculosis: a multicentre prospective cohort study in China","volume":"59","author":"Zheng","year":"2022","journal-title":"Eur Respir J."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.3389\/fmicb.2020.01182","article-title":"Wild-type MIC distribution for re-evaluating the critical concentration of anti-TB drugs and pharmacodynamics among tuberculosis patients from South India","volume":"11","author":"Dusthackeer","year":"2020","journal-title":"Front Microbiol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"3316","DOI":"10.1128\/AAC.03014-15","article-title":"MIC of Delamanid (OPC-67683) against Mycobacterium tuberculosis clinical isolates and a proposed critical concentration","volume":"60","author":"Stinson","year":"2016","journal-title":"Antimicrob Agents Chemother."},{"key":"B65","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1093\/jac\/dkp262","article-title":"Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis","volume":"64","author":"Sch\u00f6n","year":"2009"},{"key":"B66","doi-asserted-by":"publisher","first-page":"e00092","DOI":"10.1128\/AAC.00092-19","article-title":"Isoniazid resistance in Mycobacterium tuberculosis is a heterogeneous phenotype composed of overlapping MIC distributions with different underlying resistance mechanisms","volume":"63","author":"Ghodousi","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"B67","doi-asserted-by":"publisher","first-page":"e3001721","DOI":"10.1371\/journal.pbio.3001721","article-title":"A data compendium associating the genomes of 12,289 Mycobacterium tuberculosis isolates with quantitative resistance phenotypes to 13 antibiotics","volume":"20","year":"2022","journal-title":"PLoS Biol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/ng.2656","volume":"45","author":"Ford","year":"2013","journal-title":"Nat Genet."},{"key":"B69","doi-asserted-by":"publisher","first-page":"e0159421","DOI":"10.1128\/spectrum.01594-21","volume":"10","author":"Shanmugam","year":"2022","journal-title":"Microbiol Spectr"}],"container-title":["Frontiers in Tuberculosis"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/ftubr.2025.1667354\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T05:28:26Z","timestamp":1758778106000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/ftubr.2025.1667354\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":69,"alternative-id":["10.3389\/ftubr.2025.1667354"],"URL":"https:\/\/doi.org\/10.3389\/ftubr.2025.1667354","relation":{},"ISSN":["2813-7868"],"issn-type":[{"value":"2813-7868","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"article-number":"1667354"}}